Dave Lashmet Triple Play Research – Which Biotech Stocks Could Soar 100%?

Biotech Stocks Could Soar

Stansberry Venture Technology editor Dave Lashmet has spent more than two decades parsing the data to identify small-cap biotech stocks with big upside potential. And he knows that by focusing on a handful of common-sense medical and investment metrics, you can more easily tell the winners from the losers… and get in before Big Pharma catches on.